Jonathan Violin was named Chief Executive Officer of Korsana Biosciences, Inc. As of November 6, 2026, Korsana Biosciences, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on September 11, 2026, naming 1 appointment (Form 8-K, September 11, 2026).
Korsana Biosciences, Inc. named a new Chief Executive Officer on Sep 11. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Korsana Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Korsana Biosciences, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-09-11. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Korsana Biosciences, Inc. files it.
Also on the record for Korsana Biosciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 15, 2026 | Stake report, Schedule 13G/A, by J. Wood Capital Advisors LLC | 0.1% of the class | 5%+ stakes | Source |
| October 7, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 6.9% of the class | 5%+ stakes | Source |
| September 18, 2026 | Stake report, Schedule 13G, by GENERAL ATLANTIC, L.P. | 6.8% of the class | 5%+ stakes | Source |
| September 16, 2026 | Stake report, Schedule 13G, by Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. | 6.1% of the class | 5%+ stakes | Source |
| September 15, 2026 | Stake report, Schedule 13D, by Venrock Healthcare Capital Partners III, L.P. | 9.9% of the class | 5%+ stakes | Source |
| September 11, 2026 | Stake report, Schedule 13D, by Fairmount Funds Management LLC | 19.99% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by ADAR1 Capital Management, LLC | 7% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by BALYASNY ASSET MANAGEMENT L.P. | 7.33% of the class | 5%+ stakes | Source |
| July 20, 2026 | Stake report, Schedule 13D/A, by Peter M. Hecht | 19.4% of the class | 5%+ stakes | Source |
| May 7, 2026 | Stake report, Schedule 13G, by FMR LLC | 15% of the class | 5%+ stakes | Source |
| October 17, 2025 | Stake report, Schedule 13G, by J. Wood Capital Advisors LLC | 5.4% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Tyndall Capital Partners, L.P. | 4.8% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Korsana Biosciences, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Korsana Biosciences, Inc. and the records around it.
Korsana Biosciences, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- J. Wood Capital Advisors LLC also filed stake reports on 1 other company: Karyopharm Therapeutics Inc. (Nov 2025)
- Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. also filed stake reports on 2 other companies: ProMIS Neurosciences, Inc. (Aug 2026), MBX Biosciences (Nov 2025)
- GENERAL ATLANTIC, L.P. also filed stake reports on 10 other companies: dLocal Ltd (Aug 2026), Pharvaris N.V. (Aug 2026), Liftoff Mobile, Inc. (Jun 2026)
Watch Korsana Biosciences, Inc.
Get an email when Korsana Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Korsana Biosciences, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Korsana Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Korsana Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-11 | In | Chief Executive Officer | 8-K, 2026-09-11 |
Who leads Korsana Biosciences, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Executive Officer: Jonathan Violin, appointed (filed 2026-09-11).
New leaders reset buying decisions — get the Full Report on Korsana Biosciences, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at Korsana Biosciences, Inc., with the record behind each one.
Find candidates like Chief Executive Officer at Korsana Biosciences, Inc.Every change, in the filing's words
Appointed: Jonathan Violin, Chief Executive Officer
On September 8, 2026, the Board appointed Jonathan Violin, Ph.D. as the Company's Chief Executive Officer and President, Mark Vignola, Ph.D. as the Company's Chief Financial Officer and Matthew Leoni, M.D. as the Company's Chief Medical Officer, each to serve at the discretion of the Board.
- Departure of Directors and Certain Officers On September 8, 2026, Errol B. De Souza, Ph.D., Regina M. Graul, Ph.D., Peter M. Hecht, Ph.D., Michael Higgins, Steven E. Hyman, M.D. and Dina Katabi, Ph.D. resigned from the Company's board of directors and its committees on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company's operations, policies or practices.
- In addition, on September 8, 2026, Regina M. Graul, Ph.D., Cyclerion's President and Chief Executive Officer, and Rhonda M. Chicko, Cyclerion's Chief Financial Officer, each resigned as an executive officer of the Company at the Closing.
- Subject to execution of a release, Dr. Graul is eligible to receive the severance benefits and transaction bonus described in the Proxy Statement/Prospectus in the section entitled "Cyclerion Executive Compensation".
- The departures of Dr. Graul and Ms. Chicko were not the result of any disagreement with the Company relating to the Company's operations, policies or practices.
- Stock Incentive Plan On July 16, 2026, Cyclerion's board of directors approved the Korsana Biosciences, Inc. 2026 Stock Incentive Plan (the "2026 Stock Plan"), subject to shareholder approval and the consummation of the Merger.
- On August 26, 2026, Cyclerion's shareholders approved the 2026 Stock Plan at the Annual Meeting.
Tools for this story
Each opens in a new tab, filled in for Korsana Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.